Vol 4, No 4 (December 29, 2015): Chinese Clinical Oncology (Lung Cancer - Guest Editors: Jean-Pierre Armand and Liya Ju)

Preface

Preface
Jean-Pierre Armand, Liya Ju

Original Article

Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study
Gaelle Jeannin, Patrick Merle, Henri Janicot, Lise Thibonnier, Fabrice Kwiatkowski, Adel Naame, J. Baptiste Chadeyras, Géraud Galvaing, Aurélie Belliere, Marc Filaire, Pierre Verrelle
Prophylactic tracheotomy and lung cancer resection in patient with low predictive pulmonary function: a randomized clinical trials
Marc Filaire, Marie M. Tardy, Ruddy Richard, Adel Naamee, Jean Baptiste Chadeyras, Valence Da Costa, Patrick Bailly, Nathanaël Eisenmann, Bruno Pereira, Patrick Merle, Géraud Galvaing
Subclavian artery resection and reconstruction for thoracic inlet neoplasms
Olaf Mercier, Xiao-Dong Su, Benoit Lahon, Sacha Mussot, Dominique Fabre, Alexandra Delemos, Thierry Le Chevalier, Philippe G. Dartevelle, Elie Fadel

Review Article

Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
René-Olivier Mirimanoff
Extended resection of non-small cell lung cancer invading the left atrium, is it worth the risk?
Geraud Galvaing, Jean Baptiste Chadeyras, Patrick Merle, Marie M Tardy, Adel Naamee, Patrick Bailly, Marc Filaire
Methodology of clinical trials in lung cancer
Jessica Menis, Benjamin Besse, Denis Lacombe
Chemoradiotherapy for stage III non-small cell lung cancer: have we reached the limit?
Peng Xu, Cecile Le Pechoux
Autologous tracheal replacement for cancer
Dominique Fabre, Elie Fadel, Sacha Mussot, Frederic Kolb, Nicolas Leymarie, Olaf Mercier, Thierry Le Chevalier, Philippe G. Dartevelle
Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Gérard A. Milano
Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors
Sandrine Aspeslagh, Aurélien Marabelle, Jean-Charles Soria, Jean-Pierre Armand
Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
René-Olivier Mirimanoff

Disclosure:

The focused issue “Lung Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Joseph Wee, Jean-Pierre Armand and Liya Ju served as the unpaid Guest Editors for the focused issue.